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1. Introduction 
As explained previously [1], the European Directive for Medical Devices (MDs) and 
equipment, the DIR 2007/47/EC [2], aims at achieving the goal of quality of medical 
delivery at a distance, providing comparable demands in telemedicine or distance support 
as in face-to-face healthcare.  
The transposition into Spanish law of the EU directive was the Royal Decree RD-1591/2009, 
dated 16 October 2009 [3], which regulates the use of medical devices called “PRODUCTOS 
SANITARIOS (PS)” (= health-care products) in Spanish, which came into force on the 21st of 
March 2010. As from that date, the CE-Label is always required in all “MDDS or Medical 
Device Data Systems” according to the FDA. 
In this article, we will explain the philosophy behind the EU-Directive and the Spanish RD 
with respect to quality in medical assistance. We will also try to demonstrate that the same 
norms apply to Telemedicine, and we will finally underline the importance of training 
medical and health-care workers in those aspects linked to the Body of Knowledge of 
Telemedicine as well as in the essential safety aspects linked to medical assistance. These 
professionals may indeed be guilty of infringing the law and liable if the law is not applied.  
As is well known, ignorance of the law is no excuse. This has indirect consequences on the 
training and licensing of health-workers.  
2. Medical device- definitions 
According to the EU directive and the transposed RD:  
The definition of an MD in the RD (in Spanish) is based on the European Commission 
Directive 2007/47/ec which defines a medical device as <<any instrument, apparatus, 
appliance, software, material or other article, whether used alone or in combination, 
including the software intended by its manufacturer to be used specifically for diagnostic 
and/or therapeutic purposes and necessary for its proper application, intended by the 
manufacturer to be used for human beings. Devices are to be used for the purpose of: 
• Diagnosis, prevention, monitoring, treatment or alleviation of disease. 
• Diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap. 
• Investigation, replacement or modification of the anatomy or of a physiological process. 
• Control of conception. 
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This includes devices that do not achieve its principal intended action in or on the human 
body by pharmacological, immunological or metabolic means, but which may be assisted in 
its function by such means.>> 
An MD is not a medicine in the sense that it does not produce its principal effect inside or on 
the surface of the body by pharmacological, immunological, or metabolically active 
substances, but whose function may contribute to them. 
The so-called “in vitro” diagnostic systems are not covered by the 1591/2009 decree; they 
are regulated by the RD-1662/2000 decree. 
The goal of the EU directive as well as that of the RD is to guarantee a quality system for 
MDs with periodic inspection and control by means of 5 distinct procedures: 
1. EXAMINATION of the CE type is defined as the procedure by which a NOTIFIED  
BODY tests a representative sample of the product and certifies that it is in accordance 
with the RD demands.  The result is the CERTIFICATION of the MD-type. 
2. CE-VERIFICATION is defined as the procedure by which the MANUFACTURER or 
its authorized representative guarantees and declares that the products are in 
conformity with the MD-Type described in the certification of the CE-examination, 
and that they fulfill all the requirements set out in the RD. The conformity declaration 
includes a statement according to which the manufacturer agrees to guarantee the 
product after its sale and installation and to correct any defect that could occur.   
 
This means that the manufacturer must implement all required controls and tests linked to the MD-
type. 
 
3. & 4. CE DECLARATION OF CONFORMITY for the PRODUCTION and the 
PRODUCT is defined as the procedure by which the MANUFACTURER puts into 
practice all warranty requirements and declares that all the products are in conformity 
with the MD-type described in the Certificate of the CE-examination, and that they 
fulfill all the requirements set up in the RD.  
 
This means that the manufacturer must implement the whole quality system to assure conformity 
not only of the final product but of the whole production. 
 
Part of this task is to guarantee the organizational structures and the responsibility of 
the directives, the methods of efficacy in the function, and the control to third parties, 
whenever applicable. 
Furthermore, a VALIDATION REPORT should accompany those MDs whose 
function is “measurements”. 
 
This is the case of Telemetry and distance measurement that require a VALIDATION REPORT 
before being authorized for use in real world situations. This is an important qualitative difference 
from the previous situation in which software systems had to be validated by the users and hospital 
before being used. Now, the software as an MD requires a previous Validation Report by the 
manufacturer. 
 
Similarly, the manufacturer whose products require “connection with other products” to 
work must provide proof that their products fulfill the essential requirements once 
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connected to other products according to the manufacturer’s goal or to those specified as a 
special purpose (custom made1, research2, etc.). 
 
This means that for any product connected to another to send information, the manufacturer must 
guarantee that this information is not altered in any way (manipulation, lost information, lossy 
compression, encryption, etc… ), and must not be integrated without a Validation Report.  
In other words, the manufacturer is responsible for the integration processes, whether added 
functions are included or not. 
 
5. CE-LABEL.  Only those products with a CE-Label will be authorized to appear on the 
market and to be used in medical practice. The CE-label will always be accompanied 
by the identification of the Notified Organ responsible for the evaluation procedures.  
Exceptions for the CE-Label are: 
a. As an exception, products or devices built for one person or for clinical research do 
not require CE-Label.   
b. For medical devices and products for which the Certificate of Conformity does not 
require the intervention of the NOTIFIED BODY (these are the Type I devices), 
the CE-Label will not carry an identification number assigned by the Notified 
Body.  
 
This means that the CE-label is mandatory for all MDs or Health Products, but that those included 
in the Type I group will not carry an identification number. 
 
c. According to the RD, CE-Label conformity is not required for those MDs that are 
not included in article 2, paragraph 1, points a) and b)-   
 
Therefore, the CE-Label only applies to MDs together with their ACCESSORIES. 
 
To ensure the product guarantee, the manufacturer must be able to demonstrate CE-Label 
conformity during a period of 5 years, but for implantable MDs or products, the period is 15 
years. This information must be available to the authorities in charge of quality control.   
 
Therefore, in order to claim for any malfunctioning or defect of the product, we should understand 
the terms defined in the law, particularly the term MANUFACTURER. 
 
Custom-made devices are intended for the sole use by a particular patient and produced in 
accordance with specifications prescribed by a qualified practitioner. A mass-produced MD 
that only needs adaptation is not a custom made device. Custom- made devices do not carry 
a visible CE mark, but remain subject to the Medical Device Directive (MDD) requirements. 
                                                 
1 ‘Custom made’ means that the device is for one patient only and should carry his/her name as well as 
the name of the medical doctor who authorized it (encrypted or not) along with the medical 
prescription. 
2 Guarantee for patients in the trial, permission from the ethical committee as well as  the medical 
doctor and center authorization must be provided. 
www.intechopen.com
 Advances in Telemedicine: Technologies, Enabling Factors and Scenarios 
 
264 
The manufacturer must issue a statement of conformity for each device stating the patient's 
name, device identification, and responsible medical practitioners. 
2.1 Definitions 
In the RD the following terms of importance are defined:  
Manufacturer: the person or legal entity responsible for the design, manufacture, packaging 
and labeling of the MD to be introduced on the market in his own name, regardless of 
whether any of these operations are carried out by the same person/entity or by a third 
party. 
Introduction on the market: this term refers to the first time an MD or Health product, not 
designed for clinical research, arrives on the market with or without economic transaction 
(i.e., for free), for its distribution and/or use in the EU market, regardless of whether it is a 
new or a totally refurbished product. 
 
This means that a manufacturer is a person or legal entity who produces an MD whether it is for 
financial profit or not, whether it is produced voluntarily or by contract or even by mandate within 
an organization in a public or a private system, provided that the medical device is used in the real 
world (i.e., not only for research) in a country member state of the EU. 
 
Commercialization: any provision, with or without economic transaction (i.e., for free), for 
its distribution or use in the EU market during a commercial activity. 
 
This means the real use of the product coming from a manufacturer to a final user for its real use, 
regardless of whether the transaction  involves financial gain or not. 
 
Deployment: refers to the phase in which a product, prepared to be marketed in the EU for 
the first time according to the manufacturer’s intended goal, is given to the final user. 
Goal assignation: The use for which the MD is built according to the indications of the 
manufacturer in the labeling of the product, user’s instructions and/or marketing material 
or flyers. 
 
This means that, although the manufacturer does the product either by contact, for free o  
by obligation, the device should have, before any use, a label with user’s instructions and a  
detailed specification explaining why the system was built and validated for according to the 
manufacturer. 
 
Medical specialist: a medical doctor or any other person with accredited professional 
qualifications who is legally authorized to issue a medical prescription or to perform 
biomedical research. 
 
This means that the validation of a system must be performed, tested and supervised by a specialized 
medical doctor. 
Obviously, a medical specialist must supervise medical assistance from the very start, whether this 
assistance is provided for research or for regular assistance. 
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Promoter: manufacturer, legal representative or any other person or organization that 
becomes responsible for the indications and/or deployment of a clinical research. 
 
This means that a promoter is a person who indicates an MD “deployment” by giving it to the final 
user for free or after payment. This activity is usually performed by the local health-care authorities 
with MDs and products of the software and telemetry types, specifically designed at a regional or 
“in house” level for local healthcare use. 
 
Chapter II of the RD specifies that the manufacturers should be registered and should 
possess a previous license to operate in order to make sure that they have an organizational 
structure capable of guaranteeing the quality of their products and the performance of the 
procedures and controls mentioned above. They have to have a technical responsible 
personnel, with an university-licensure (title) that assure an ad-hoc qualification to control 
and supervise the product in charge; furthermore, his availability for this task must be 
demonstrated devoting a sufficient labor time-schedule. Finally he should carry out a series 
of documents to collect all information produced during product-manufacture. These 
documents should include the design, production and capabilities of the product so as to 
check the conformity of the product to the essential requirements (i.e in a software application 
to encrypt clinical information in order to send it at distance, documents should demonstrate that the 
application fulfill the data-protection law. This could avoid for example the case to steal and 
disseminate sensitive information located in the memory chip of the printers once those are replaced or 
even when those are repaired…)   
 
If this is the case, local health-authorities that produce their own software for medical-clinical-
assistance should be registered and required to fulfill the same demands as any other manufacturer. 
And of course, once in public call for tender, it should be mandatory to include those requisites for 
enterprises applying the call to build ”regional” or “in house” assistant systems. 
 
However, the RD also mentions that the Spanish Agency of Medications and Health 
Products could authorize, in an individualized and specific manner and based on health 
care considerations, the marketing and deployment of products that have not satisfied all 
the validation procedures indicated in article 13. 
 
We hope that, for the final users’ safety, there will be few such exceptions to the norm, and that this 
provision for exceptions will never become a repetitive practice. An example of the use of this 
exceptional authorization put into practice in the case of medication was the vaccination campaign 
against influenza A (H1N1): the vaccine did not fulfill all the requirements to be on the market. 
3. Essential information & definitions relevant for health care workers 
The RD starts a procedure to understand the design, manufacture and applications of the 
product together with the design, risk analysis, investigation and clinical trials etc., with 
respect to product safety, including electromagnetic compatibility and radiation protection, 
as well as ergonomic design and the level of training of future users3. 
                                                 
3 Training should also involve the medical doctors as users. 
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That means that the manufacturer must train users to assure that they will use the device in a 
proper manner, without risk for patients and health care workers, and to make sure that they know 
their liability when using it. Therefore, the liability for the products and devices introduced on the 
market is the manufacturers.  
This also clearly applies to local healthcare authorities if they act as manufacturers.  
 
As specified above, based on the level of potential risk to the human body, MDs are 
classified as one of four types: types I, IIa, IIb y III. 
The higher the number, the greater the risk. In the lowest risk class (type I MD), the 
evaluation is the exclusive responsibility of the manufacturer. For the other types, the 
evaluation is performed by a “NOTIFIED BODY” appointed by national authorities to issue 
a Certificate of Conformity.  
 
As we will see, most Telemedicine systems are classified as type I MDs because they are not 
invasive. Thus, they do not require a number or a Certificate of Conformity from the “Notified 
Body”. Nevertheless, it is mandatory for them to carry the CE-label. This means that, under the 
responsibility of the manufacturer, the device must meet the requirements for quality and safety 
demanded for any MD and be supported by documents proving that verification and manufacture 
control etc., have been carried out. These documents must be available to the competent authorities 
in case of any legal demand or claim.  
A problem arises when the so-called “competent authority” coincides with the manufacturer or is 
the entity that establishes the system requirements in the call for tenders. 
 
This is why all MDs require initial classification by the manufacturer as one of four types for 
the CE-label, as follows: 
Type I- NON INVASIVE PRODUCTS4, with the exception of those connected to higher type 
numbers or in contact with human body substances, fluids or tissues. These comprise all 
PSANI-Producto Sanitario Activo No Invasivo (in English: non-invasive Active Medical 
Device) with the exception of the cases that we will study further on.  
INVASIVE PRODUCTS FOR A SHORT PERIOD OF TIME (less than 60 min) and those used 
in the natural orifices  (oral cavity up to the pharynx, external ear conduct up to the 
tympanic membrane, nasal cavity). 
Type II-ALL INVASIVE PRODUCTS, including the PSA-Productos Sanitarios Activos (In 
English: Active Medical Devices). These exclude invasive surgical devices connected to a 
type I MD. This group is divided into two sub-groups, as follows: 
IIa-  MDs USED for A LIMITED PERIOD OF TIME (up to 30 days). This includes those used 
in wounds or around micro-wounds and surgical invasive devices, except those used for 
monitoring, diagnosis, surveillance, and cardio-circulatory correction. Those invasive to 
natural orifices that are connected to a PSA type IIa (active device type IIa). Dental implants. 
All products for diagnosis or surveillance of non-critical vital signs5 and those involved with 
the introduction of non-harmful substances in the body. Products used for disinfection.  
IIb- MDs USED FOR LONG PERIODS OF TIME (more than 30 days). Those MDs or 
products carrying ionizing radiation, having a biologic effect, capable of being absorbed by 
                                                 
4 All active software and telemedicine devices belong to this group. 
5 Among these are all telemetry systems (including vital sign telemetry if the patient is not in a critical 
condition. It therefore refers to the classical home-care), tele-ultrasonography, etc. 
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the human body or capable of being modified by it. Any active MD connected to a type IIb6 
or PSAI -Producto Sanitario Activo Invasivo ( In English: Invasive Active Medical Device). 
This includes all MDs for the surveillance of critical vital signs7 and those that are 
potentially harmful8 because they introduce substances into the body. Blood bags. 
Contraceptives. Contact lenses, disinfection products. 
Type IIb also include all implantable products, with the exception of dental implants, 
cardio-vascular or central nervous system implants, and those that produce chemical or 
biological changes in the human body.  
Type III-  Surgical instruments which are in contact with the Central Nervous System and 
cardio-vascular system, or MDs that are absorbed or produce a biological or chemical 
modification in the human body. Products containing human blood or derived products 
(hemo-derivatives). Contraceptive devices used for long periods of time. All products that 
contain animal tissue or their derivatives.   
The RD specifies that any substantial changes in an MD or Health product must be notified 
to the “Notified Body”. The RD specifies that all MDs, health care products and their 
ACCESSORIES must carry the CE-label, numbered by the Notified Organism, except for 
Type I MDs which must exhibit the CE-label, but which are not numbered.  
 
Type I-MDs, despite carrying a non-numbered CE-Label (which means that the product is not 
certified by a “Notified Body”), must be supported by documents demonstrating that the product 
has been subjected to the same quality control process. These documents will be required any time 
by the authorities when claims or civil and penal liability arise. 
 
The Royal Decree, which is complex to understand, aims at implementing international 
standards on quality control in  the production, design and vital cycle of the product, such 
as the  UNE EN 60601-1:2008, IEC 60601-1/2005, ISO 14971:2007, IEC 62304:2006, etc. 
 
This means that those devices showing the CE-label must provide a guarantee of information (there 
will be no secret products); of security (required to be tested in clinical trials); of functionality (they 
require a previous validation before marketing and real functioning); of quality design (they should 
have a quality design ISO-13485). If not, the device or product can only be considered as a 
demonstrator[6].  
3.1 Definitions 
In the previous paragraphs, we defined what is considered a MEDICAL DEVICE or a 
HEALTH CARE PRODUCT. Here we introduce definitions relevant for health-care workers, 
such as: 
An MD or PRODUCT FOR CLINICAL INVESTIGATION: this is an MD or product devoted 
to a medical specialist9 to carry out the research in an adequate clinical human environment. 
                                                 
6 i.e: more than 30 days Home-care. 
7 Vital sign telemetry including EEG y EEC. 
8 Harmful for the organ or due to the type of substance.  
9 This means that a telemetry system or a telemedicine device cannot be in the hands of an engineer 
(Take into consideration that innovation units, tele-ictus units and so on… are leader by engineers) nor 
the i+D+D projects that involve clinical research or clinical trials.  
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A RE-USABLE SURGICAL INSTRUMENT is one that is not connected to an active MD or 
PSA. 
An ACTIVE-MD or PSA (implantable-PSAI or non- implantable-PSANI) is any MD that 
requires electrical power or any other energy source different from the one coming from the 
human body, or that is due to gravity, and that transforms this energy (i.e., telemetry 
systems). All SOFWARE PROGRAMES are considered  Active-MDs. Excluded from this 
group are those MDs used for transmitting provided that there is no significant 
modification, energy, substances or other elements from an active-MD to the patient.  
The criteria of Software programs are those that allow diagnosis, treatment, follow up, prevention, 
whether or not they include artificial intelligence. The latter could be as a completely autonomous or 
when those results are taken by healthcare workers to make decisions with respect to a local or distant 
patient (at home; tele-ictus; anti-cloth treatment; telemedicine in general). And although 
administrative computer programs (HIS-Hospital information system) will probably be excluded 
from future regulation, the EMR or Electronic Medical Record is directly linked to them. The EMR 
contains essential elements for patients’ treatment or follow up that involve liability of medical 
doctors, such as medical orders, or electronic prescription requiring a legally recognized digital 
signature, and that in any case requires strict QUALITY CONTROL and therefore should be 
included in the RD. Many EMR and applications for e-prescriptions contain decision rules on 
treatment protocols, assistance to the diagnosis, prescription, patient surveillance or follow up that 
transform them into an Active-MD that requires active quality control [7].  
The problem arises when those computer programs without quality control are developed and updated 
by the health-care authorities either at the national or regional or local level as “in house” “custom” 
products for health-care. In private healthcare entities, quality control could be easy to provide since 
the company responsible for marketing and supplying those products for real use is in effect the 
manufacturer and is subject to control by the local authorities. However, in local public authorities 
the manufacturer and the controller may be the same entity. This is so even if the manufacturer is an 
outside company contracted through a call for tenders, since the requirements for the design are 
established by the local authority and in many cases this is limited to compatibility with other in-
house applications and not to manufacturing quality control. Being aware that manufacturing 
quality control items are titles and preparation of the developers, legal-preparation, time devoted for 
the technical personnel in the design, who is responsible for the life cycle of the product, who is 
responsible for the necessary technical migration in 3-5 years time to update technology and security 
( i.e. electronic signature, cipher according to law, to adapt to registration and certification 
organisms, management of new parameters and medical devices, etc….). And more specifically in 
wireless active-MD (telemetry) or not ( WIFI hospitals) the degree of interaction of their magnetic 
fields with other monitoring or measurement systems are not verified or tested properly because the 
assembly is done “in house” without verification of the quality control. 
This is regardless of the requirements of CONFORMITY which are defined as an MD 
following national norms taken to implement harmonized standards to fulfill essential 
requirements and officially published in the Government bulletins. 
  
Thus, software manufacturers will be responsible during the whole active-life of the product. Being 
Type I or low risk MDs, the products will not require auditing by law, except if there is a claim, but 
as medical software, they will be regulated by the IEC 62304:2006 standard. 
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The European Commission stresses the need to use standards in order to ensure 
connectivity that should include semantic and technical norms, and physics of connectors 
and cables. However, national standards that determine the connectivity of telemetry and 
telemedicine systems are still to be established. 
With respect to telemedicine, the minimum connectivity specified by the WHO is the IEEE 
11073 [8]. Following the guide for validation of automatic systems (GAMP- Good 
Automated Manufacturing Practice)[9], bioengineering hospital services should control the 
operative systems, the hardware and the software embedded in the systems, as well as 
COTS (Commercial-off-the-shelf) software, configurable systems and any modification of 
PIMS (Personal Information Manager Software). 
Furthermore the CMM or Capability Maturity Model for software[10] in their version 1.3 
established VALIDATION and VERIFICATION at level 3, requiring thereafter level 4 or the 
quantization of processes and level 5 of Optimization.  And it should be kept in mind that in 
many software health-care applications, even level 3 is missing[11]. 
4. USA ahead 
As predicted elsewhere [12], the Obama health reform has forced the adoption of medicine 
at a distance (telemedicine) in order to optimize resources and reduce costs in the system. 
The USA are very concerned about quality control and have created several government 
organizations to guarantee the quality control of medical assistance, standardization and 
connectivity, establishing minimum requirements to obtain a quality label. One of the most 
interesting bills passed by the US Congress is the ARRA (the American Recovery and 
Reinvestment Act of 2009) aimed at stimulating  the use of IT (Information Technology), but 
what is surprising is the provision for penalties after 2015 for those professionals and 
organizations that do not use connective solutions. [13].  
We will therefore see the time when those responsible for education and health-care will 
accept that all these technologies have to be integrated into the professional training. This 
implies that telemedicine and bioengineering applied to telemedicine will become core 
subject matters in the university degree of Medicine [14]. 
5. Summary 
The transposition of the EU Directive DIR 2007/47/EC into European countries will 
improve the quality of the Telemedicine software and devices [15][16]. Nevertheless, health-
care authorities have not yet understood the important requirements and the level of 
changes they will have to introduce. This is in part due to the fact that this information is not 
taken into consideration in the training of health care professionals. 
The discipline of Telemedicine and e-health is mature if we take into consideration the level 
of standards existing nowadays. In contrast, maturity of the IT applications in health care is 
far from being optimal. This is in part because we associate maturity with penetration and 
not with quality, and mechanisms to ensure a quality control of the applications are still to 
be built.  
Abbreviations 
AIQ Analytical Instrument Qualification | CFR Code of Federal Regulations | CSV 
Computer System Validation | EMEA European Medicine Evaluation Agency | EU 
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European Union | FDA U.S. Food and Drug Administration | GAMP Good Automated 
Manufacturing Practice | GLP Good Laboratory Practice | GMP Good Manufacturing 
Practice | ISMS Information Security Management System | ISO International 
Organization for Standardization | USP United States Pharmacopeia 
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Telemedicine services can range from simply sending a fax message to a colleague to the use of broadband
networks with multimodal video- and data streaming for second opinioning as well as medical telepresence.
Telemedicine is more and more evolving into a multidisciplinary approach. This book project "Advances in
Telemedicine" has been conceived to reflect this broad view and therefore has been split into two volumes,
each covering specific themes: Volume 1: Technologies, Enabling Factors and Scenarios; Volume 2:
Applications in Various Medical Disciplines and Geographical Regions. The current Volume 1 is structured into
the following thematic sections: Fundamental Technologies; Applied Technologies; Enabling Factors;
Scenarios.
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